The feature articles in this issue of BETA offer a prismatic look at treatment issues that may particularly concern people who have been living with HIV and taking antiretroviral treatments for some time. Fatigue is a common side effect of both HIV itself and antiretroviral treatment, and is common in people with more advanced HIV disease. See "HIV-Related Fatigue".

"Dual Protease Inhibitors Gain Ground" explores an increasingly popular approach to protease inhibitors (PIs), namely, using small doses of ritonavir (Norvir) in combination with other PIs to achieve a regimen that is theoretically more potent and also easier to take. With Kaletra (lopinavir/ritonavir) as a focal point, Dave Gilden discusses the background and rationale for boosted or dual PIs. So far, Kaletra looks promising for people with HIV who have already exhausted a number of antiretroviral options, and shows efficacy even in people with PI resistance.

Another angle on the issue of long-term antiretroviral therapy and adverse effects is what role the U.S. Food and Drug Administration (FDA) plays or might play to anticipate and manage drug side effects—basically, to safeguard consumers. Many drugs for HIV were approved rapidly through an accelerated approval mechanism for which many HIV activists lobbied, so as to provide access to potentially life-saving drugs to people with no other treatment options. Yet subsequent developments, such as the continued emergence of long-term side effects (e.g., so-called lipodystrophy) that are at least in part related to treatment, have caused many to reevaluate the best way to speedily yet safely allow drugs to be placed on the market. Reinvigorating or enforcing a tool already in place, the so-called Phase IV of clinical testing, might be one approach (see "Monitoring Anti-HIV Medicines: What Is the FDA’s Role?").

Also in this issue are our regular departments. This edition of Conference Coverage features a comprehensive look at the encouraging variety of anti-HIV medications in the pipeline, as presented a few months ago in Chicago at the 8th Conference on Retroviruses and Opportunistic Infections (CROI), which has become the preeminent annual science conference for HIV/AIDS.

In the Global Epidemic, we profile Botswana in order to provide a perspective on HIV-related news and effects from a region that is highly impacted by HIV. In fact, Botswana is the country with the highest seroprevalence rate in the world: prevalence among adults is estimated to be 35.8%, and increasing. It is hard not to use the word "staggering" when describing the situation in Botswana. Yet many admirable efforts are underway to combat HIV from a number of directions, no small feat in a country where, despite attempts to better educate all children, illiteracy and a large rural population—among other factors—complicate HIV treatment and prevention efforts.

010410
BE010401

Copyright © 2001 - San Francisco AIDS Foundation. Reproduced by permission. Reproduction of this article (other than one copy for personal reference) must be cleared through BETA: PO Box 426182, San Francisco, CA 94142-6182. Tel: 415 487 8060 Fax: 415 487 8069 URL: http://www.sfaf.org/beta E-mail: beta@sfaf.org

ÆGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990, 2001. ÆGiS & the Sisters of Saint Elizabeth of Hungary. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS, or the party credited as the provider of the content.